Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

Active:	Yes
Cancer Type:	Bile Duct Cancer Gallbladder Cancer	NCT ID:	NCT06109779
Trial Phases:	Phase III	Protocol IDs:	D7025C00001 (primary) NCI-2024-04612 2023-506054-20-00
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	AstraZeneca Pharmaceuticals LP
NCI Full Details:	http://clinicaltrials.gov/show/NCT06109779

Summary

A global study to assess the efficacy and tolerability of rilvegostomig compared to
placebo in combination with investigator's choice of chemotherapy in participants with
BTC after surgical resection with curative intent.

Objectives

This is a Phase III, randomized, double-blind, placebo-controlled, multicenter, global
study to assess the efficacy and tolerability of rilvegostomig compared to placebo in
combination with investigator's choice of chemotherapy (capecitabine, S-1(tegafur/
gimeracil/ oteracil) or gemcitabine/cisplatin) as adjuvant treatment in participants with
BTC after resection with curative intent. This study will be conducted in patients with
BTC who are at risk of recurrence after resection with curative intent.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.